Ulka Vaishampayan, MD, is a Professor of Internal Medicine, Leader of the Translational and Clinical Research Program, and the Director of the Phase 1 Program at the University of Michigan Rogel Cancer Center. In 2022 she was endowed with Beverly S. Mitchell, M.D. Research Professorship in Cancer Research. She serves as the Chair of the SWOG Advanced Renal Committee, a member of the National Cancer Institute (NCI) Renal Task Force, and a board member of the Michigan Society of Hematology/Oncology.
Dr. Vaishampayan specializes in the treatment of genitourinary malignancies, including prostate cancer, bladder cancer, and renal cell carcinoma, and her research focuses on translational drug development. She is PI of the Department of Defense Kidney Cancer Consortium site and a recipient of the Prostate Cancer Foundation Challenge Award. She has completed leadership training and has acquired the prestigious Fellowship of the Advisory Board (FAB). She has 250+ publications in a number of peer-reviewed journals such as the New England Journal of Medicine, Journal of Clinical Oncology, and Clinical Cancer Research.
